2021-2022年度最新SCI期刊列表数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 期刊名字 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY CRIT REV ONCOL HEMAT LetPub评分 7.6
50人评分
我要评分
声誉 8.8 影响力 6.7 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 1040-8428 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| 2021-2022最新IF （数据来源于搜索引擎） | 登录后查看IF和趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 3.10%登录查看自引率趋势图 | |||||||||||||||||||||
| h-index | 111 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy. | |||||||||||||||||||||
| 期刊官方网站 | http://www.croh-online.com/ | |||||||||||||||||||||
| 期刊投稿网址 | http://ees.elsevier.com/croh | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||||||
| 出版商 | Elsevier Ireland Ltd | |||||||||||||||||||||
| 涉及的研究方向 | 医学-血液学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 250登录查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 10.52% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 0.00% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月最新基础版） | 登录查看中科院JCR分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月最新升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index (已不再单独更新，统称SCIE) Science Citation Index Expanded (SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1040-8428%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 偏慢,4-8周 来源Elsevier官网： 平均27.3周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 一般 来源Elsevier官网： 83% | |||||||||||||||||||||
| 在线出版周期 | 来源Elsevier官网： 平均8.8周 | |||||||||||||||||||||
| 期刊常用信息链接 | ||||||||||||||||||||||
|
|
| |
| 登录查看自引率趋势图 |
| 登录查看中科院JCR分区趋势图 |
| 登录查看年文章数趋势图 |
| 中国学者近期发表的论文 | |
| 1. | Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials Author: Yuguang Zhao, Wenhui Liu, Meiting Sun, Qiuli Miao, Yingmin Liu, Huimin Tian, Yapin Su, Fujun Han Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 39-46, DOI:10.1016/j.critrevonc.2019.01.017 DOI |
| 2. | The roles of EBV-encoded microRNAs in EBV-associated tumors Author: Min Dong, Jian-ning Chen, Jun-ting Huang, Li-ping Gong, Chun-kui Shao Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 30-38, DOI:10.1016/j.critrevonc.2019.01.014 DOI |
| 3. | Corrigendum to “Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy” [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110–117] Author: Bin Zhao, Hong Zhao, Jiaxin Zhao Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 20, DOI:10.1016/j.critrevonc.2019.01.007 DOI |
| 4. | Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data Author: Jie Ying, Jinfei Chen Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol., , DOI:10.1016/j.critrevonc.2019.01.001 DOI |
| 5. | Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials Author: Jing Li, Jian Gu Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, Vol.134, 31-38, DOI:10.1016/j.critrevonc.2018.12.001 DOI |
| 6. | Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review Author: Jing Lu, Xiang-dong Sun, Xi Yang, Xin-yu Tang, Qin Qin, Hong-cheng Zhu, Hong-yan Cheng, Xin-chen Sun Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, Vol.107, 128-137, DOI:10.1016/j.critrevonc.2016.08.015 DOI |
| 7. | Aptamers in hematological malignancies and their potential therapeutic implications Author: Wanyan Ouyang, Ziqiang Yu, Xiaohong Zhao, Shiyun Lu, Zhi Wang Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, Vol.106, 108-117, DOI:10.1016/j.critrevonc.2016.08.003 DOI |
| 8. | TP53 dysfunction in diffuse large B-cell lymphoma. Author: Lu TX, Young KH, Xu W, Li JY. Journal: Crit Rev Oncol Hematol. 2016 Jan;97:47-55. doi: 10.1016/j.critrevonc.2015.08.006. Epub 2015 Aug 10. Review. PubMed |
| 9. | Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapy. Author: Shan NN, Dong LL, Zhang XM, Liu X, Li Y. Journal: Crit Rev Oncol Hematol. 2016 Apr;100:11-5. doi: 10.1016/j.critrevonc.2016.01.011. Epub 2016 Jan 19. Review. PubMed |
| 10. | Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis. Author: Flamini V, Jiang WG, Lane J, Cui YX. Journal: Crit Rev Oncol Hematol. 2016 Apr;100:177-89. doi: 10.1016/j.critrevonc.2016.02.010. Epub 2016 Feb 18. Review. PubMed |
|
|
| 首页 上一页 下一页 尾页 (第0/0页) | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共0条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2022 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
